"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity? Curr Cardiol Rep. 2024 Sep; 26(9):1011-1019.
-
Emerging Role of Semaglutide and GLP-1 Agonist Medications in Plastic Surgery: A Note of Caution. Plast Reconstr Surg. 2024 09 01; 154(3):629e-631e.
-
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo. Ann Intern Med. 2024 Mar; 177(3):JC31.
-
A Plethora of GLP-1 Agonists: Decisions About What to Use and When. Curr Diab Rep. 2016 12; 16(12):120.
-
Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning? Diabetes. 2014 Jul; 63(7):2219-21.
-
GLP-1R agonist therapy for diabetes: benefits and potential risks. Curr Opin Endocrinol Diabetes Obes. 2013 Apr; 20(2):87-97.
-
Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. Am J Physiol Gastrointest Liver Physiol. 2012 Jan 15; 302(2):G218-24.
-
Feeding an elemental diet vs a milk-based formula does not decrease intestinal mucosal growth in infant pigs. JPEN J Parenter Enteral Nutr. 2006 Jan-Feb; 30(1):32-9.
-
Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets. Am J Physiol Gastrointest Liver Physiol. 2006 Feb; 290(2):G293-300.
-
Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Comp Physiol. 2006 Feb; 290(2):R283-9.